182 related articles for article (PubMed ID: 30488457)
21. Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.
Zhao FJ; Zhang S; Yu ZM; Xia SJ; Li H
Prostate Cancer Prostatic Dis; 2009; 12(2):166-71. PubMed ID: 18626508
[TBL] [Abstract][Full Text] [Related]
22. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
Ghosh A; Heston WD
J Cell Biochem; 2004 Feb; 91(3):528-39. PubMed ID: 14755683
[TBL] [Abstract][Full Text] [Related]
23. Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2012 Jun; 29(2):835-41. PubMed ID: 21573974
[TBL] [Abstract][Full Text] [Related]
24. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.
O'Keefe DS; Bacich DJ; Heston WD
Prostate; 2004 Feb; 58(2):200-10. PubMed ID: 14716746
[TBL] [Abstract][Full Text] [Related]
26. Bispecific oligonucleotides may induce interferon expression in LNCaP cells enhancing surface antigen expression: effect of intrastrand base pair complementarity.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2011; 25(1):61-7. PubMed ID: 21282736
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway.
Guo Z; Lai Y; Du T; Zhang Y; Chen J; Bi L; Lin T; Liu H; Wang W; Xu K; Jiang C; Han J; Zhang C; Dong W; Huang J; Huang H
Chin Med J (Engl); 2014; 127(5):929-36. PubMed ID: 24571890
[TBL] [Abstract][Full Text] [Related]
28. Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model.
Dzojic H; Cheng WS; Essand M
Cancer Gene Ther; 2007 Mar; 14(3):233-40. PubMed ID: 17053814
[TBL] [Abstract][Full Text] [Related]
29. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells.
Cao KY; Xu L; Zhang DM; Zhang XM; Zhang T; He X; Wang Z; Feng FS; Qiu SP; Shen GX
Int J Oncol; 2012 Jun; 40(6):1977-85. PubMed ID: 22322627
[TBL] [Abstract][Full Text] [Related]
30. A Novel Role of Prostate-Specific Membrane Antigen in Telomere Stability in Prostate Cancer Cells.
Reddy V; Hwang C; Reddy GP; Kim SH
Mol Cancer Res; 2023 Nov; 21(11):1176-1185. PubMed ID: 37477641
[TBL] [Abstract][Full Text] [Related]
31. SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction.
Fan R; He H; Yao W; Zhu Y; Zhou X; Gui M; Lu J; Xi H; Deng Z; Fan M
DNA Cell Biol; 2018 Feb; 37(2):126-132. PubMed ID: 29271667
[TBL] [Abstract][Full Text] [Related]
32. PSMA-PSA clones controlled by full Akt phosphorylation (T308+,S473+) recapitulate molecular features of human prostate cancer.
Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Horchani A; Oueslati R
Tunis Med; 2015; 93(8-9):556-64. PubMed ID: 26815524
[TBL] [Abstract][Full Text] [Related]
33. SOX7 transcription factor: sequence, chromosomal localisation, expression, transactivation and interference with Wnt signalling.
Takash W; Cañizares J; Bonneaud N; Poulat F; Mattéi MG; Jay P; Berta P
Nucleic Acids Res; 2001 Nov; 29(21):4274-83. PubMed ID: 11691915
[TBL] [Abstract][Full Text] [Related]
34. Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for
Bakht MK; Lovnicki JM; Tubman J; Stringer KF; Chiaramonte J; Reynolds MR; Derecichei I; Ferraiuolo RM; Fifield BA; Lubanska D; Oh SW; Cheon GJ; Kwak C; Jeong CW; Kang KW; Trant JF; Morrissey C; Coleman IM; Wang Y; Ahmadzadehfar H; Dong X; Porter LA
J Nucl Med; 2020 Jun; 61(6):904-910. PubMed ID: 31806771
[TBL] [Abstract][Full Text] [Related]
35. [Transcriptional activities of tumor-specific survivin promoter and PSMA promoter and enhancer in human prostate cancer: evaluation and comparison].
Luo XM; Liu JY; Su MQ; Hao XK
Zhonghua Nan Ke Xue; 2012 Feb; 18(2):122-5. PubMed ID: 22568207
[TBL] [Abstract][Full Text] [Related]
36. Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
Hwang JE; Joung JY; Shin SP; Choi MK; Kim JE; Kim YH; Park WS; Lee SJ; Lee KH
Cancer Lett; 2016 Mar; 372(1):57-64. PubMed ID: 26723876
[TBL] [Abstract][Full Text] [Related]
37. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
[TBL] [Abstract][Full Text] [Related]
38. Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2010 Dec; 27(4):1212-8. PubMed ID: 19937163
[TBL] [Abstract][Full Text] [Related]
39. [Construction and expression of recombinant plasmid with prostate-specific membrane antigen promoter and enhancer regulating uracil phosphoribosyltransferase gene].
Zhao FJ; Li H; Cheng HM; Zeng H; Wei Q; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):172-5. PubMed ID: 15807258
[TBL] [Abstract][Full Text] [Related]
40. Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostate-specific membrane antigen promoter and enhancer.
Zhang P; Zeng H; Wei Q; Lu Y; Li X; Wang J; Zhao F; Li H
Int J Urol; 2008 May; 15(5):442-8. PubMed ID: 18452463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
